Eli Lilly and Company (NYSE: LLY) shares have appreciated by approximately 6% over the last month, driven by strong market demand for its metabolic treatments, Mounjaro and Zepbound. Analysts from Leerink and Berenberg recently raised their price targets to $1,232 and $1,135 respectively, citing positive...
Eli Lilly and Company (LLY) concluded the first half of 2026 with a significant rally, pushing its stock price to a 52-week high of $1,207.59. The primary drivers for this performance were the demonstrated efficacy of retatrutide in treating severe obesity and robust sales figures...
Eli Lilly has entered into a new collaboration agreement with Abbisko Therapeutics, a subsidiary of oncology specialist Abbisko Cayman, to jointly discover, develop, and potentially commercialize experimental medicines across multiple targets. The partnership focuses on early-stage drug programs aimed at accelerating the advancement of innovative...
Eli Lilly (LLY) and Pfizer (PFE) reported contrasting Q1 2026 results, with Lilly dominating the obesity market while Pfizer rebuilds post-pandemic. Lilly generated $19.80B in revenue, a 55.5% increase driven by Mounjaro ($8.66B) and Zepbound ($4.16B), achieving a 65% volume rise despite a 13% price...
Eli Lilly (LLY) is facing intensified valuation scrutiny amidst social media discussions regarding its recent acquisition of 4E Therapeutics to expand chronic pain management. While observers note the strategic nature of this tuck-in deal, there are growing concerns about elevated stock multiples and potential red...
Claris Financial LLC acquired a new stake in Eli Lilly and Company (LLY) valued at approximately $1.01 million during the fourth quarter, according to recent SEC filings. Several other institutional investors also adjusted their positions, with Brighton Jones LLC increasing holdings by 22.0% and Revolve...
On June 9, the US FDA approved a new eight-week maintenance dosing regimen for Eli Lilly's (LLY) EBGLYSS (lebrikizumab-lbkz). This approval allows adults and children aged 12 and older with moderate-to-severe atopic dermatitis to receive a single injection once every eight weeks, reducing the frequency...
Eli Lilly (NYSE: LLY) has reached a $1 trillion market cap, driven by its dominant position in the GLP-1 weight loss market with products like Mounjaro and Zepbound. While the stock is up modestly this year, it has delivered over 400% returns over the last...
Eli Lilly and Novo Nordisk reported divergent Q1 2026 results that highlight a shifting landscape in the obesity drug market. Eli Lilly grew revenue by 55.5% and raised guidance, driven primarily by tirzepatide products Mounjaro and Zepbound, which saw significant year-over-year growth fueled by international...
Eli Lilly (LLY) shares rose approximately 3.7% on Thursday, trading near $1,123 per share. If this price level is maintained, the company would achieve its first record closing stock price for the year 2026, surpassing the previous high of $1,109.94 set on November 25 of...
Jim Cramer highlighted on Friday that both Apple and Eli Lilly still possess significant upside potential following their recent post-earnings rallies. The S&P 500 reached a fresh intra-day high, driven largely by gains in Apple, which is part of the "Mag Seven" comeback according to...
On CNBC's Fast Money panel, there was a significant shift in perspective regarding two major biotechnology companies, Novo Nordisk (NVO) and Eli Lilly (LLY), suggesting that Novo Nordisk has become more appealing to investors. This change in sentiment follows a substantial decline for Novo Nordisk,...
Eli Lilly (LLY) stock surged nearly 10% on Thursday following the release of strong Q1 earnings, driven primarily by exceptional sales of its GLP-1 drugs, Zepbound and Mounjaro. These medications are used for weight management and diabetes, with Zepbound revenue climbing 80% year over year...
On April 9, 2026, Amazon announced that its pharmacy unit will begin stocking Eli Lilly's new GLP-1 weight-loss pill, Foundayo, at One Medical kiosks with same-day home delivery plans to reach 4,500 locales by the end of 2026. This expansion integrates Amazon Pharmacy as a...
Eli Lilly and Company (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) reported contrasting quarterly results in early February that have widened the competitive gap between the two giants in the obesity drug market. Lilly's fourth-quarter revenue surged to $19.29 billion, representing a 42.6% year-over-year...
Amazon is significantly expanding access to Eli Lilly’s newly approved weight-loss pill, known as Foundayo, by integrating it into its pharmacy operations and logistical network. According to CNBC, Amazon Pharmacy will begin stocking the medication at kiosks located within select One Medical primary care clinics,...
Eli Lilly and Company (LLY) shares closed the session up 1.82% at $1,008.39, outperforming the S&P 500's gain of 0.83%, the Dow's 0.5%, and the Nasdaq's 1.38%. However, despite this daily gain, the stock has depreciated by 6.41% over the past month, underperforming both the...
